Kalbe Farma Tbk PT
XMUN:LCLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kalbe Farma Tbk PT
XMUN:LCLA
|
ID |
|
B
|
Baidu Inc
XBER:B1CB
|
CN |
|
E
|
EDP Renovaveis SA
DUS:EDW
|
ES |
|
D
|
Draganfly Inc
F:3U8A
|
CA |
Wall St Price Targets
LCLA Price Targets Summary
Kalbe Farma Tbk PT
According to Wall Street analysts, the average 1-year price target for LCLA is 0.065 EUR with a low forecast of 0.041 EUR and a high forecast of 0.089 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is LCLA's stock price target?
Price Target
0.065
EUR
According to Wall Street analysts, the average 1-year price target for LCLA is 0.065 EUR with a low forecast of 0.041 EUR and a high forecast of 0.089 EUR.
What is the Revenue forecast for Kalbe Farma Tbk PT?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 3 years is 9%.
What is the Gross Profit forecast for Kalbe Farma Tbk PT?
Projected CAGR
11%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 3 years is 11%.
What is the Operating Income forecast for Kalbe Farma Tbk PT?
Projected CAGR
6%
Over the last 13 years, the compound annual growth rate for Operating Income has been 6%. The projected CAGR for the next 3 years is 6%.
What is the Pre-Tax Income forecast for Kalbe Farma Tbk PT?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 6%. The projected CAGR for the next 3 years is 3%.
What is the Net Income forecast for Kalbe Farma Tbk PT?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next 3 years is 8%.
